Jeff Yass’s Acumen Pharmaceuticals ABOS Stock Holding History

Jeff Yass’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Buy	59,400 +3,400	+6%	+$8.4K	﹤0.01%	12159
2026 Q1	$132K	Buy	+56,000	New	+$143K	﹤0.01%	12134
2025 Q3	–	Sell	-17,200	Closed	-$20K	–	12234
2025 Q2	$20K	Buy	+17,200	New	+$18.5K	﹤0.01%	12335
2024 Q4	–	Sell	-54,800	Closed	-$136K	–	12073
2024 Q3	$136K	Sell	54,800 -104,800	-66%	-$284K	﹤0.01%	10828
2024 Q2	$386K	Sell	159,600 -82,000	-34%	-$261K	﹤0.01%	8880
2024 Q1	$978K	Buy	241,600 +82,700	+52%	+$312K	﹤0.01%	6973
2023 Q4	$610K	Buy	158,900 +53,100	+50%	+$158K	﹤0.01%	8177
2023 Q3	$439K	Sell	105,800 -35,300	-25%	-$218K	﹤0.01%	8536
2023 Q2	$679K	Buy	141,100 +98,800	+234%	+$473K	﹤0.01%	7593
2023 Q1	$172K	Buy	42,300 +7,100	+20%	+$37.1K	﹤0.01%	10786
2022 Q4	$190K	Sell	35,200 -85,200	-71%	-$572K	﹤0.01%	10206
2022 Q3	$1.21M	Buy	+120,400	New	+$691K	﹤0.01%	6144

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Jeff Yass's ABOS Position: Q2 2026 in Review

Jeff Yass reduced its Acumen Pharmaceuticals (ABOS) stake by 79% in Q2 2026, selling an estimated $1.17M and leaving 126,104 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #10790.

Jeff Yass first reported a position in ABOS in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.92M in Q4 2023. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Jeff Yass held 126,104 shares of Acumen Pharmaceuticals worth $337K as of Q2 2026.
Jeff Yass sold 475,372 Acumen Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
Acumen Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10790 holding.
Jeff Yass first reported a position in Acumen Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Jeff Yass's Acumen Pharmaceuticals position peaked at $1.92M in Q4 2023.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.